Evidence map›Paper›PMID 34498780›Full record

ArticleThe oncologist2021

Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies.

Oscar Arrieta, Luis Lara-Mejía, Elysse Bautista-GonzÁlez, David Heredia, Jenny G Turcott, Feliciano BarrÓn, Maritza Ramos-Ramírez, Luis Cabrera-Miranda, Miguel Ángel Salinas Padilla, Mercedes Aguerrebere and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Assessment of Cancer Patients' Mental Health during the Coronavirus Pandemic in Serbia.International journal of environmental research and public health · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Oscar ArrietaThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.ORCID 0000-0002-1164-3779
Luis Lara-MejíaThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.ORCID 0000-0001-8101-4604
Elysse Bautista-GonzÁlezInstitute of Epidemiology and Public Health, University College London, London, United Kingdom.
David HerediaThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.ORCID 0000-0003-3798-5950
Jenny G TurcottThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.ORCID 0000-0003-2614-1656
Feliciano BarrÓnThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.ORCID 0000-0002-1401-4011
Maritza Ramos-RamírezThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Luis Cabrera-MirandaThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Miguel Ángel Salinas PadillaThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Mercedes AguerrebereInstituto Nacional de Psiquiatría, Mexico City, Mexico.ORCID 0000-0001-5951-4047
Andrés F CardonaClinical and Translational Oncology Group, Clínica del Country, Bogota, Colombia.ORCID 0000-0003-3525-4126
Christian RolfoCenter for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai, New York, New York, USA.ORCID 0000-0002-7860-8417
Marisol Arroyo-HernÁndezThoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.ORCID 0000-0003-0115-811X
Enrique Soto-Pérez-de-CelisInstituto Nacional de Ciencias Médicas y Nutrición y Salvador Zubirán (INCMNSZ), Mexico City, Mexico.ORCID 0000-0002-7301-2163
Renata Baéz-SaldañaInstituto Nacional de Enfermedades Respiratorias (INER), Mexico City, Mexico.
Instituto Nacional de Cancerología · MXInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXInstituto Nacional de Enfermedades Respiratorias · MXInstituto Nacional de Pediatria · MXMount Sinai Health System · USUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccumulated evidence indicates that patients with lung cancer are a vulnerable population throughout the pandemic. Limited information is available in Latin America regarding the impact of the pandemic on medical care. The goal of this study was to describe the clinical and social effect of COVID-19 on patients with thoracic cancer and to ascertain outcomes in those with a confirmed diagnosis. MATERIALS AND

methodsThis cohort study included patients with thoracic neoplasms within a single institution between March 1, 2020, and February 28, 2021. All variables of interest were extracted from electronic medical records. During this period, the Depression Anxiety and Stress Scale 21 (DASS-2) was applied to evaluate and identify more common psychological disorders.

resultsThe mean age for the total cohort (n = 548) was 61.5 ± 12.9 years; non-small cell lung cancer was the most frequent neoplasm (86.9%), advanced stages predominated (80%), and most patients were under active therapy (82.8%). Any change in treatment was reported in 23.9% of patients, of which 78.6% were due to the COVID-19 pandemic. Treatment delays (≥7 days) were the most frequent modifications in 41.9% of cases, followed by treatment suspension at 37.4%. Patients without treatment changes had a more prolonged progression-free survival and overall survival (hazard ratio [HR] 0.21, p < .001 and HR 0.28, p < .001, respectively). The mean DASS-21 score was 10.45 in 144 evaluated patients, with women being more affected than men (11.41 vs. 9.08, p < .001). Anxiety was reported in 30.5% of cases, followed by depression and distress in equal proportions (18%). Depressed and stressed patients had higher odds of experiencing delays in treatment than patients without depression (odds ratio [OR] 4.5, 95% confidence interval [CI] 1.53-13.23, p = .006 and OR 3.18, 95% CI 1.2-10.06, p = .006, respectively).

conclusionTreatment adjustments in patients with thoracic malignancies often occurred to avoid COVID-19 contagion with detrimental effects on survival. Psychological disorders could have a role in adherence to the original treatment regimen. IMPLICATIONS FOR PRACTICE: The pandemic has placed an enormous strain on health care systems globally. Patients with thoracic cancers represent a vulnerable population, with increased morbidity and mortality rates. In Mexico, treatment modifications were common during the pandemic, and those who experienced delays had worse survival outcomes. Most treatment modifications were related to a patient decision rather than a lockdown of health care facilities in which mental health impairment plays an essential role. Moreover, the high case fatality rate highlights the importance of improving medical care access. Likewise, to develop strategies facing future threats that may compromise health care systems in non-developed countries.

Indexed as

Carcinoma, Non-Small-Cell LungCOVID-19Lung NeoplasmsThoracic NeoplasmsAgedAnxietyCohort StudiesCommunicable Disease ControlDepressionFemaleHumansMaleMexicoMiddle AgedPandemicsSARS-CoV-2Coronavirus disease 2019Lung cancerPandemicSevere acute respiratory syndrome coronavirus 2Thoracic neoplasms

Identifiers

PMID34498780
PMCPMC8649017
OpenAlexW3198091128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.